We have located links that may give you full text access.
Case Reports
Journal Article
Review
Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature.
BACKGROUND: Pyoderma gangrenosum (PG) is an idiopathic ulcerative neutrophilic inflammatory skin disease characterized by variable clinical presentation and outcome. Because its incidence is low, no prospective randomized controlled trials and only a few large case studies on PG have been reported.
OBSERVATIONS: We demonstrate the clinical presentation and outcome in 18 cases with severe and chronic PG. In our 18 patients, the female/male ratio was 3.5:1, the mean onset age was 53.1 yrs (range 23-78); six cases (33%) had associated diseases (inflammatory bowel disease [n = 2, 11%], monoclonal gammopathy [n = 2, 11%], rheumatoid arthritis [n = 1, 6%], diabetes mellitus [n = 1, 6%]). Anatomic locations involved were lower leg (n = 14, 78%), abdomen (n = 5, 28%), arm (n = 3, 17%), breast (n = 2, 11%), and buttocks (n = 1,6%). Five patients (28%) had multiple lesions (n > or = 2). Immunosuppressive monotherapies (n = 3, 17%) and polytherapies (n = 15, 83%) were used. 13 patients (72%) showed complete remission (mean duration to complete remission: 1.29 yrs), three patients (17%) persistent disease (mean duration: 8 yrs), contact was lost to one patient (6%) and one patient died (6%).
CONCLUSION: Our observations add to the growing body of evidence that PG responds in most cases to systemic immunosuppressive treatment, with corticosteroids and cyclosporine representing first-line therapies. Besides reporting the clinical outcome in our 18 patients, we review the literature and discuss treatment recommendations that take additional factors including associated conditions, disease severity and localization of lesions into consideration.
OBSERVATIONS: We demonstrate the clinical presentation and outcome in 18 cases with severe and chronic PG. In our 18 patients, the female/male ratio was 3.5:1, the mean onset age was 53.1 yrs (range 23-78); six cases (33%) had associated diseases (inflammatory bowel disease [n = 2, 11%], monoclonal gammopathy [n = 2, 11%], rheumatoid arthritis [n = 1, 6%], diabetes mellitus [n = 1, 6%]). Anatomic locations involved were lower leg (n = 14, 78%), abdomen (n = 5, 28%), arm (n = 3, 17%), breast (n = 2, 11%), and buttocks (n = 1,6%). Five patients (28%) had multiple lesions (n > or = 2). Immunosuppressive monotherapies (n = 3, 17%) and polytherapies (n = 15, 83%) were used. 13 patients (72%) showed complete remission (mean duration to complete remission: 1.29 yrs), three patients (17%) persistent disease (mean duration: 8 yrs), contact was lost to one patient (6%) and one patient died (6%).
CONCLUSION: Our observations add to the growing body of evidence that PG responds in most cases to systemic immunosuppressive treatment, with corticosteroids and cyclosporine representing first-line therapies. Besides reporting the clinical outcome in our 18 patients, we review the literature and discuss treatment recommendations that take additional factors including associated conditions, disease severity and localization of lesions into consideration.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app